
Mabwell to Unveil Phase 2 Data on Nectin-4 ADC at ESMO 2026
Clinical researchers will shift their focus to the potential of the Nectin-4-targeting antibody-drug conjugate 9MW2821 this October, as Shanghai-based biopharmaceutical firm Mabwell prepares to present new results from a Phase 2 study at the 2026 European Society for Medical Oncology Annual Congress in Madrid.












:format(jpg)/f.elconfidencial.com%2Foriginal%2F08d%2F58d%2F796%2F08d58d79656e645b90cf331561961452.jpg)










